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Abstract
The predominant mechanism of drug resistance in African trypanosomes is decreased drug uptake due to loss-of-function
mutations in the genes for the transporters that mediate drug import. The role of transporters as determinants of drug
susceptibility is well documented from laboratory-selected Trypanosoma brucei mutants. But clinical isolates, especially of T.
b. gambiense, are less amenable to experimental investigation since they do not readily grow in culture without prior
adaptation. Here we analyze a selected panel of 16 T. brucei ssp. field isolates that (i) have been adapted to axenic in vitro
cultivation and (ii) mostly stem from treatment-refractory cases. For each isolate, we quantify the sensitivity to melarsoprol,
pentamidine, and diminazene, and sequence the genomic loci of the transporter genes TbAT1 and TbAQP2. The former
encodes the well-characterized aminopurine permease P2 which transports several trypanocides including melarsoprol,
pentamidine, and diminazene. We find that diminazene-resistant field isolates of T. b. brucei and T. b. rhodesiense carry the
same set of point mutations in TbAT1 that was previously described from lab mutants. Aquaglyceroporin 2 has only recently
been identified as a second transporter involved in melarsoprol/pentamidine cross-resistance. Here we describe two
different kinds of TbAQP2 mutations found in T. b. gambiense field isolates: simple loss of TbAQP2, or loss of wild-type
TbAQP2 allele combined with the formation of a novel type of TbAQP2/3 chimera. The identified mutant T. b. gambiense are
40- to 50-fold less sensitive to pentamidine and 3- to 5-times less sensitive to melarsoprol than the reference isolates. We
thus demonstrate for the first time that rearrangements of the TbAQP2/TbAQP3 locus accompanied by TbAQP2 gene loss
also occur in the field, and that the T. b. gambiense carrying such mutations correlate with a significantly reduced
susceptibility to pentamidine and melarsoprol.
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Introduction
The chemotherapy of human African trypanosomiasis (HAT,
also known as sleeping sickness) currently relies on suramin or
pentamidine for the first, haemolymphatic stage and on melarso-
prol or eflornithine/nifurtimox combination therapy (NECT) for
the second stage, when the trypanosomes have invaded the central
nervous system (CNS) [1]. All five drugs have unfavorable
pharmacokinetics and adverse effects. Melarsoprol is particularly
toxic, causing severe encephalopathies in over 5% of the treated
patients [2]. And yet, melarsoprol is the only treatment for late-
stage T. b. rhodesiense infections. New and safer drugs are at various
stages of (pre)clinical development, thanks largely to the Drugs for
Neglected Diseases initiative (www.dndi.org). Two molecules that
have successfully passed clinical Phase I trials are now being tested
in patients: the nitroimidazole fexinidazole [3,4] and the
benzoxaborole SCYX-7158 [5,6]. Both are orally available and
cure 2nd stage T. b. brucei infections in a mouse model [7].
However, until new drugs for HAT are on the market, the current
ones – problematic as they are – need to be used in a sustainable
way. This requires an understanding of the mechanisms of drug
resistance.
The mechanisms of drug resistance in African trypanosomes
have been studied in the lab for over 100 years [8]. Two
observations were made recurrently, namely (i) reduced drug
uptake by drug resistant trypanosomes [9–14] and (ii) cross-
resistance between melarsoprol and pentamidine [15,16]. Both
phenomena were attributed to the fact that melarsoprol and
pentamidine are taken up by trypanosomes via the same
transporters, which appeared to be lacking in drug-resistant
mutants. The first transporter identified was called P2 since it was
one of two purine nucleoside transporters identified [17,18]. It is
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encoded by the gene TbAT1 for adenine/adenosine transporter 1
[19]. Homozygous genetic deletion of TbAT1 in bloodstream-form
T. b. brucei resulted in pentamidine and melarsoprol cross-resistance,
albeit only by a factor of about 2.5 [20]. This weak phenotype,
together with the fact that the TbAT12/2 mutants still exhibited
saturable drug import [21], indicated that further transporters are
involved in melarsoprol-pentamidine cross-resistance [16,21,22].
One such transporter was recently identified, the aquaglyceroporin
TbAQP2 [23,24]. Aquaporins and aquaglyceroporins belong to the
major intrinsic protein (MIP) family and form channels that
facilitate transmembrane transport of water and small non-ionic
solutes such as glycerol and urea [25]. The three aquaporins of T.
brucei (TbAQP1-3) are thought to physiologically function as
osmoregulators and are involved in glycerol transport [26].
Aquaporins were described to mediate uptake of arsenite in
mammalian cells [27] and in Leishmania, and loss of aquaporin
function was implicated in heavy metal resistance [28]. Homozy-
gous genetic deletion of TbAQP2 in bloodstream-form T. b. brucei
increased the IC50 towards melarsoprol and pentamidine by about
2- and 15- fold, respectively [24]. Moreover, a T. b. brucei lab mutant
selected for high-level pentamidine resistance [21] carried a
chimeric TbAQP2 gene, where 272 nucleotides had been replaced
by the corresponding sequence from a neighboring, very similar
gene TbAQP3 [24]. Differences in the TbAQP2/TbAQP3 tandem
locus on chromosome 10 were also observed between the reference
genome sequences of T. b. gambiense DAL972 [29] and T. b. brucei
TREU927 [23,30]. They possess identical versions of TbAQP2 but
differ in TbAQP3 [31]. More recent field isolates of T. brucei ssp. have
so far not been genotyped regarding their TbAQP2/TbAQP3 locus.
The genotypic status of TbAT1, located proximal to a telomere
on chromosome 5 [32], has been more intensely investigated.
Point mutations in TbAT1 were described, both in selected lab
strains and in clinical T. brucei ssp. isolates, which rendered the
gene non-functional when expressed in yeast [19]. The occurrence
of these mutations correlated to a certain degree with melarsoprol
treatment failure in 2nd stage T. b. gambiense HAT patients [33–36].
However, the relationship between polymorphisms in TbAT1,
drug susceptibility, and treatment failure in patients is not fully
resolved as the TbAT1 mutant T. b. gambiense were not analyzed
phenotypically. Such investigations are notoriously difficult since
clinical T. b. gambiense isolates are hard to obtain (given the
inaccessibility of HAT foci and the poor success rate of isolation
and adaptation in rodents) and cannot readily be propagated in
axenic culture. Here we concentrate on clinical T. brucei ssp.
isolates from drug refractory cases that have been adapted to
axenic in vitro cultivation, aiming to investigate whether mutations
at the known melarsoprol and pentamidine transporter loci also
occur in the field – and if so, whether such mutations are
accompanied by loss of drug susceptibility.
Materials and Methods
Trypanosoma brucei ssp. isolates
The 16 analyzed isolates are described in Table 1 (origin) and
Table 2 (clinical outcome). For more details on the recent isolates
from the DRC please refer to Table S4 of Pyana et al (2011) [37].
All have previously been adapted to axenic cultivation. T. b. brucei
and T. b. rhodesiense isolates were cultured in minimum essential
medium (MEM) with Earle’s salts with the addition of 0.2 mM 2-
mercaptoethanol, 1 mM Na-pyruvate, 0.5 mM hypoxanthine,
and 15% heat-inactivated horse serum as described by Baltz et al
(1985) [38]. T. b. gambiense strains were cultured in IMDM
medium supplemented according to Hirumi and Hirumi (1989)
[39], plus 0.2 mM 2-mercaptoethanol, 15% heat-inactivated fetal
calf serum and 5% human serum. The cultures were maintained
under a humidified 5% CO2 atmosphere at 37uC and were
subpassaged 3 times a week to ensure growth in the exponential
(log) phase.
Phenotyping
Drug sensitivity was determined with the Alamar blue assay as
described by Ra¨z et al (1997) [40], using the redox-sensitive dye
resazurin as an indicator of cell number and viability. The
trypanosomes were cultivated in 96-well microtiter plates in serial
dilutions of drugs for 70 h. 10 ul of resazurin (125 ug/ml (Sigma)
dissolved in PBS pH 7.2) was added to each well. The plates were
further incubated for 2–4 hours for T. b. rhodesiense and T. b. brucei,
and 6–8 hours for T. b. gambiense, before being read with a
SpectraMax Gemini XS microplate fluorescence scanner (Molec-
ular Devices) at an excitation wavelength of 536 nm and an
emission wavelength of 588 nm. IC50 values were calculated by
non-linear regression to a sigmoidal inhibition curve using
SoftMax Pro software (V. 5.2). The IC50 values given in Table 2
are averages 6 standard deviation of at least 3 independent assays
(n = 3–12), each determined in duplicate. Melarsoprol (Sanofi-
Aventis) was obtained from WHO. Pentamidine isothionate and
diminazene aceturate were purchased from Sigma.
Genotyping
Genomic DNA was isolated from 10 ml dense trypanosome
cultures. The cells were spun down and the pellets resuspended in
300 ml 10 mM TrisHCl pH 8, 1 mM EDTA and 3 ml 10% SDS
was added before incubating for 10–15 min at 55uC. After 5 min
incubation 3 ml of pronase mix (20 mg/ml, Sigma) was added to
increase the stability of the extracted DNA. 90 ml of ice cold 5 M
potassium acetate was added and the mixture was incubated for
5 min on ice. After spinning down for 5 minutes at max speed in a
microfuge, the supernatant was transferred to a new tube and
DNA was precipitated in 2–2.5 volumes of absolute ethanol,
washed in 70% ethanol and dissolved in 20 ml ddH2O. PCR was
performed with Taq polymerase (Solis BioDyne, Estonia); the
primers and annealing temperatures are summarized in Table S1.
Author Summary
Human African Trypanosomiasis, or sleeping sickness, is a
fatal disease restricted to sub-Saharan Africa, caused by
Trypanosoma brucei gambiense and T. b. rhodesiense. The
treatment relies on chemotherapy exclusively. Drug
resistance in T. brucei was investigated mainly in labora-
tory-selected lines and found to be linked to mutations in
transporters. The adenosine transporter TbAT1 and the
aquaglyceroporin TbAQP2 have been implicated in sensi-
tivity to melarsoprol and pentamidine. Mutations in these
transporters rendered trypanosomes less susceptible to
either drug. Here we analyze T. brucei isolates from the
field, focusing on isolates from patients where melarsoprol
treatment has failed. We genotype those isolates to test for
mutations in TbAQP2 or TbAT1, and phenotype for
sensitivity to pentamidine and melarsoprol. Six T. b.
gambiense isolates were found to carry mutations in
TbAQP2. These isolates stemmed from relapse patients and
exhibited significantly reduced sensitivity to pentamidine
and melarsoprol as determined in cell culture. These
findings indicate that mutations in TbAQP2 are present in
the field, correlate with loss of sensitivity to pentamidine
and melarsoprol, and might be responsible for melarsoprol
treatment failures.
Transporter Mutations in T. brucei Field Isolates
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PCR products were run on a 0.8% agarose gel and purified on a
silica membrane column (Nucleospin gel and PCR clean up,
Macherey Nagel, Germany). The purified PCR products were
directly sequenced (Microsynth, Switzerland or GATC, Germany)
with the same primers as used for PCR amplification. Only the
TbAQP2/TbAQP3 locus of T. b. gambiense K03048 produced two
PCR products, which were cloned in pCR2.1-TOPO (Invitrogen).
The assembled sequences were submitted to GenBank; accession
numbers are listed in Table S2.
Results
A panel of Trypanosoma brucei ssp. field isolates
To be able to compare – and possibly correlate – genotype and
phenotype of T. brucei ssp., we assembled a set of 16 isolates that
had been adapted to axenic in vitro cultivation as blood-stream
forms. These included 5 recent T. b. gambiense isolates from the
Democratic Republic of the Congo (DRC), 2 older isolates from
the Republic of Coˆte d’Ivoire and one isolate from South Sudan,
Table 1. Origin of the analyzed T. brucei isolates.
Isolate Species Origin Reference
STIB 930 Tbg Republic of Coˆte d’Ivoire, 1978 [49]
ITMAP 141267 Tbg Democratic Republic of the Congo, 1960 [50]
STIB 756 Tbg Liberia, 1981 [51]
STIB 891 Tbg Uganda, 1995 [33]
DAL 870R Tbg Republic of Coˆte d’Ivoire, 1985 [52]
DAL 898R Tbg Republic of Coˆte d’Ivoire, 1985 [52]
K03048 Tbg South Sudan, 2003 [53]
45 BT (MHOM/CD/INRB/2006/1) Tbg Democratic Republic of the Congo, 2006 [37]
130 BT (MHOM/CD/STI/2006/02) Tbg Democratic Republic of the Congo, 2006 [37]
349 BT (MHOM/CD/INRB/2006/16) Tbg Democratic Republic of the Congo, 2006 [37]
349 AT (MHOM/CD/INRB/2006/19) Tbg Democratic Republic of the Congo, 2006 [37]
40 AT (MHOM/CD/INRB/2006/07) Tbg Democratic Republic of the Congo, 2006 [37]
STIB 900 Tbr Tanzania, 1982 [52]
STIB 871 Tbr Uganda, 1994 [54]
STIB 940 Tbb Somalia, 1985 [42,55]
STIB 950 Tbb Somalia, 1985 [41]
doi:10.1371/journal.pntd.0002475.t001
Table 2. Drug sensitivity (IC50 6 SD in nM), genotypic status of TbAT1 and TbAQP2, and clinical outcome of melarsoprol treatment
of the patients.
Isolate MelB Pentamidine Diminazene TbAT1 TbAQP2 Clinics
STIB 930 9.664.5 1.960.7 21.068.5 Ref Ref Cure
ITMAP 141267 15.068.1 8.363.4 9.964.4 WT WT Cure
STIB 756 6.261.1 1.360.7 24.767.9 WT WT Unknown
STIB 891 5.360.9 1.761.4 23.362.7 WT WT Unknown
DAL 870R 4.461.7 1.161.0 5.362.2 WT WT Relapse
DAL 898R 8.965.9 1.761.2 22.7616.8 WT WT Relapse
K03048 24.869.2 81.2621.9 58.0633.6 WT deletion/chimeric Relapse
45 BT 25.968.6 91.8629.7 37.5610.8 WT chimeric Relapse
130 BT 42.3617.6 76.9622.3 12.364.5 WT chimeric Probable relapse
349 BT 26.2611.3 71.9612.4 20.063.2 WT chimeric Relapse
349 AT 25.6611.8 81.9631.8 15.461.0 WT chimeric Relapse
40 AT 22.068.0 72.2621.1 39.9616.7 WT chimeric Relapse
STIB 900 4.662.6 3.260.9 3.861.5 Ref Ref Cure
STIB 871 4.461.3 2.561.0 2016163 R allele WT Cure
STIB 940 13.667.0 3.462.0 3406218 R allele WT n.a.
STIB 950 27.669.4 1.860.4 102653.6 R allele WT n.a.
WT= identical to reference (Ref) strain, being STIB 930 for T. b. gambiense isolates and STIB 900 for T. b. brucei and T. b. rhodesiense strains.
doi:10.1371/journal.pntd.0002475.t002
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which were all isolated from patients who had relapsed after
melarsoprol chemotherapy. Other T. b. gambiense isolates from the
DRC, northwestern Uganda, and Liberia were from patients who
were successfully treated with melarsoprol or the treatment
outcome is unknown. T. b. gambiense STIB 930 is a fully drug-
susceptible lab strain that was used as a reference strain. We
further included the field isolates T. b. brucei STIB 940, T. b. brucei
STIB 950 and T. b. rhodesiense STIB 871, which are multidrug-
resistant to isometamidium, diminazene and tubercidin. The fully
drug-susceptible reference strain T. b. rhodesiense STIB 900 was
included as a reference. The different isolates and their origin are
summarized in Table 1. All isolates were genotyped regarding
TbAQP2 and TbAT1.
Naturally occurring mutations in TbAQP2
When the TbAQP2/TbAQP3 genomic locus was amplified by
PCR from the 16 T. brucei ssp. isolates, all the recent T. b. gambiense
isolates from the DRC (40 AT, 45 BT, 130 BT, 349 BT and 349
AT) exhibited a smaller band than expected for the wild-type
locus. Direct sequencing of the PCR product in each of the five
isolates revealed only one gene at the locus: a chimeric version of
TbAQP2 and TbAQP3. The first 813 bp of the open reading frame
perfectly matched TbAQP2 while the remaining 126 bp derived
from TbAQP3 (Figure 1C). These 126 bp perfectly matched to
TbAQP3 of T. b. rhodesiense STIB 900 but this exact sequence is not
found in the published genome of T. b. gambiense DAL 972. Note
that the present TbAQP2-TbAQP3 chimeric gene (Figure 1C)
differs from the one described by Baker et al. from a pentamidine-
selected T. b. brucei lab mutant (Figure 1B; [24]). T. b. gambiense
K03048 from the South Sudan also gave rise to an abnormal
pattern upon PCR amplification of the TbAQP2/TbAQP3 locus
from genomic DNA: a distinctly smaller double band instead of
the expected product, indicative of heterozygosity. The smaller
band contained the upstream region of TbAQP2 followed by the
open reading frame of TbAQP3 while the TbAQP2 open reading
frame was missing (Figure 1D). The larger band contained a
TbAQP2/3 chimera similar to that encountered in the T. b.
gambiense isolates of the DRC (Figure 1C). Point mutations in
TbAQP2 were encountered in the multidrug-resistant field isolates
T. b. brucei STIB 940, T. b. brucei STIB 950 and T. b. rhodesiense
STIB 871, all of which had the same 4 SNPs in TbAQP2 compared
to the T. b. brucei 927 reference gene (Tb927.10.14170), leading to
the amino acid change threonine159 to alanine (Figure 1E).
However, the same 4 SNPs also occurred in our drug-susceptible
reference strain T. b. rhodesiense STIB 900, so they are not likely to
be involved in the mdr phenotype [41,42] of these isolates. All other
isolates analyzed had a wild-type copy of TbAQP2. The identified
sequence polymorphisms are summarized in Table 2, GenBank
accession numbers are in Table S2.
Naturally occurring mutations in TbAT1
All of the 12 analyzed T. b. gambiense isolates were identical in
TbAT1 sequence to the reference STIB 930 as well as to the
genome strain DAL972. The previously described TbAT1R allele
[19,33] was found in the 3 mdr lines T. b. brucei STIB 940, T. b.
brucei STIB 950 and T. b. rhodesiense STIB 871. TbAT1R carries 5
coding and 4 silent mutations and a codon deletion as compared to
the reference sequence (STIB 900), and the resultant protein
appeared to be non-functional when expressed in Saccharomyces
cerevisiae [19] or re-expressed in a tbat1 null T. b. brucei (De Koning,
unpublished results). The remainder of the isolates did not possess
mutations in TbAT1 when compared to the respective reference
isolate. The GenBank accession numbers of all the sequences are
in Table S2.
Correlating TbAQP2 and TbAT1 genotype to drug
susceptibility
Drug sensitivities of the bloodstream-forms of all isolates were
determined in vitro regarding melarsoprol, pentamidine, and
diminazene. The five T. b. gambiense that possessed the chimeric
TbAQP2/3 gene (45 BT, 130 BT, 349 BT, 349 AT, 40 AT), as well
as K03048 which carries a deletion of TbAQP2 in one allele, in
addition to one chimeric TbAQP2/3 allele, all showed a similar
drug sensitivity profile with markedly increased IC50 values
towards pentamidine and, to a lesser extent, also melarsoprol
(Figure 2). IC50 values were in the range of 70–92 nM for
pentamidine and 22–42 nM for melarsoprol (Table 2); compared
to the median of the four drug sensitive T. b. gambiense lines STIB
930, STIB 891, STIB 756 and ITMAP 141267, this corresponds
to a 40- to 52-fold decrease in susceptibility to pentamidine and a
2.8- to 5.3-fold decrease for melarsoprol. The higher IC50 values of
Figure 1. Schematic view of the TbAQP2/TbAQP3 locus on chromosome 10. A) Reference locus of T. b. brucei TREU927, T. b. gambiense STIB
930 and T. b. gambiense DAL972 (minor differences in TbAQP3 are not highlighted). B) Chimera of TbAQP2 and TbAQP3 as described by Baker et al.
(2012) [24] for the in vitro selected, pentamidine-resistant T. b. brucei line B48. C) Chimera of TbAQP2 and TbAQP3 plus loss of TbAQP3 in T. b.
gambiense 40 AT, 45 BT, 130 BT, 349 BT, and 349 AT, and in one K03048 allele. D) Deletion of the TbAQP2 ORF in the other T. b. gambiense K03048
allele. E) TbAQP2 polymorphisms (C474A, G475A, C477T, T480C) in several T. b. rhodesiense and T. b. brucei isolates from East Africa (STIB 900, STIB 950,
STIB 940, and STIB 871).
doi:10.1371/journal.pntd.0002475.g001
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the isolates that carried a mutation in TbAQP2 (n = 6) compared to
the remainder (n = 10) were statistically significant both with
respect to pentamidine (p = 0.0002, two-tailed Mann-Whitney test)
and melarsoprol (p = 0.0047); no association was observed
regarding TbAQP2 status and sensitivity to diminazene. However,
the isolates that carried the known resistance allele TbAT1R (i.e.
STIB 940, STIB 950 and STIB 871) exhibited strongly increased
IC50 values to diminazene (p = 0.01, two-tailed Mann-Whitney
test) but not to pentamidine (Figure 2, Table 2). T. b. brucei STIB
950 also had an elevated IC50 against melarsoprol (Figure 2), but
over all three TbAT1R isolates there was no significant effect on
melarsoprol susceptibility.
Across all 16 T. brucei isolates, pentamidine sensitivity positively
correlated with that to melarsoprol (Spearman’s rank correlation
coefficient of 0.67, p = 0.005) while there was no correlation
between the two structurally related diamidines, pentamidine and
diminazene (Figure 2).
Discussion
It is an intriguing phenomenon with African trypanosomes that
drug resistance is predominantly linked to reduced drug import,
typically arising from loss of function mutation of a non-essential
transporter [12,19,24]. Here we investigated the aminopurine
transporter TbAT1 and the aquaglyceroporin TbAQP2, two
proteins known to be involved in uptake of – and susceptibility to –
melarsoprol and diamidines in bloodstream-form T. brucei. While
there is evidence for a link between TbAT1 mutations and
melarsoprol treatment failure in the field [33–36], the more
recently identified gene TbAQP2 has so far not been analyzed in a
clinical setting. TbAQP2 is dispensable for growth in culture [24]
and partial gene replacement of TbAQP2 with TbAQP3 was
observed in a pentamidine-selected T. b. brucei lab mutant [24] that
displayed reduced infectivity to rodents [21]. However, it was
unknown whether similar mutations also occur in the field, as they
might bear a fitness cost in patients or during transmission by the
tsetse fly. Concentrating on a panel of clinical T. brucei ssp. isolates
that (i) derived from treatment-refractory cases and (ii) had been
adapted to axenic in vitro culture, we have genotyped their TbAT1
and TbAQP2 loci, and phenotyped their in vitro sensitivity towards
melarsoprol, pentamidine and diminazene. Our aim was to
explore whether TbAQP2 mutations occur in the field and if so,
whether mutant isolates exhibit reduced drug susceptibility.
Five of the analyzed T. b. gambiense isolates, all from melarsoprol
relapse patients of Dipumba Hospital in Mbuji-Mayi, DRC,
carried only one gene at the TbAQP2/TbAQP3 tandem locus, an
unprecedented TbAQP2/3 chimera. The high degree of sequence
similarity between TbAPQ2 and TbAQP3 allows for homologous
recombination between the two genes, leading to chimerization
and gene loss. TbAQP2 has a unique selectivity filter with unusual
NSA/NPS motifs instead of the characteristic NPA/NPA that
occur in the vast majority of MIP family members [43] including
TbAQP1 and TbAQP3 [24]. The published, pentamidine-
resistant T. b. brucei lab mutant possessed a TbAQP2/3 chimera
whose C-terminal filter triplet was from TbAQP3, suggesting that
the unusual NPS triplet may be involved in pentamidine transport.
However, the presently described pentamidine-resistant T. b.
gambiense isolates carry a TbAQP2/3 chimera encoding a predicted
protein with both selectivity filter triplets from TbAQP2. We
hypothesize that the TbAQP2/3 chimera observed in the T. b.
gambiense isolates fails to contribute to pentamidine and melarso-
prol susceptibility despite having the proposed selectivity filter
residues of TbAQP2. Functional expression of the chimeric gene
in tbaqp2 null cells will be necessary to test this hypothesis.
The occurrence of rearrangements at the TbAQP2/TbAQP3
locus correlated with reduced susceptibility to pentamidine and, to
a lesser extent, melarsoprol. Thus field isolates also exhibit the well
known cross-resistance between melarsoprol and pentamidine
[15,16,31], while no cross-resistance was observed to diminazene
aceturate. This is in agreement with TbAT1 being the primary
uptake route for diminazene [44,45] and consistent with results
obtained using TbAQP22/2 cells, which showed no resistance to
the rigid diamidines diminazene or DB75 [24], as opposed to
pentamidine which has a highly flexible structure. It is also
noteworthy that T. b. rhodesiense STIB 871 and T. b. brucei STIB
940 are susceptible to melarsoprol and pentamidine in vitro
although both carry the TbAT1r allele. Loss of TbAT1 function
has been described without mutations in the open reading frame of
Figure 2. In vitro drug sensitivities. 50% inhibitory concentrations (IC50) as determined with the Alamar blue assay. Susceptibility to pentamidine
correlates with that to melarsoprol but not diminazene. TbAT1 and TbAQP2 genotypes are indicated.
doi:10.1371/journal.pntd.0002475.g002
Transporter Mutations in T. brucei Field Isolates
PLOS Neglected Tropical Diseases | www.plosntds.org 5 October 2013 | Volume 7 | Issue 10 | e2475
the gene [32]. However, since in the present study all isolates with
a ‘wild-type’ TbAT1 ORF were fully susceptible to diminazene, we
conclude that they possess a functional TbAT1 (i.e. P2) transporter.
Trypanosoma congolense and T. vivax appear to lack an AT1 orthologue
[46], therefore diminazene transport and resistance must have a
different mechanism in these livestock parasites.
The plasma levels of pentamidine in treated patients peak about
1 hour after injection and vary extensively from 0.42 mM to
13 mM, while the mean elimination half-life after multiple
applications is approximately 12 days [47]. Thus, since pentam-
idine is very potent, even a 50-fold increase in IC50 of pentamidine
as observed here for the T. b. gambiense isolates with mutations in
TbAQP2, is unlikely to jeopardize the success of treatment. With
melarsoprol, however, the obtainable drug levels are more critical.
Only 1–2% of the maximal plasma levels are seen in the CSF [48],
and a 5-fold reduced sensitivity to melarsoprol might allow
trypanosomes to survive in the CSF during melarsoprol therapy.
Thus mutations in TbAQP2 might indeed be responsible for
melarsoprol treatment failures with T. b. gambiense. However, two
of the T. b. gambiense isolates from relapse patients (DAL 870R and
DAL 898 R) were sensitive to melarsoprol and pentamidine, and
they possessed wild-type copies of TbAT1 and TbAQP2, indicating
that factors other than drug resistance can contribute to treatment
failures. Larger sample sizes will be required to test the significance
of TbAQP2 for successful treatment. We show here for the first
time that a TbAQP2/3 chimera as well as loss of TbAQP2 occurs in
T. b. gambiense clinical isolates, and that the presence of such
rearrangements at the TbAQP2/TbAQP3 locus is accompanied by
a 40- to 50-fold loss in pentamidine sensitivity and a 3- to 5-fold
loss in melarsoprol sensitivity. We recommend genotyping of the
TbAQP2/TbAQP3 locus to be integrated into larger field trials such
as clinical studies with drug candidates.
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